Blueprint’s pipeline also includes other promising candidates such as BLU-808, an oral wild-type KIT inhibitor being developed for chronic spontaneous urticaria (CSU) and other allergic conditions.

Blueprint Medicines (NASDAQ: BPMC) Corporation, a commercial-stage biotechnology company with a market capitalization of $8.27 billion, has been making significant strides in the pharmaceutical ...

In conclusion, Blueprint Medicines stands at a pivotal juncture with its recent acquisition by Sanofi and the continued success of Ayvakit. The stock has demonstrated strong momentum, with a 37.31% ...

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a a ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts. Why it matters ...

Blueprint Medicines (BPMC) shares are soaring after Sanofi (SNY) agreed to acquire the company for up to $9.5 billion. Boeing (BA) shares were upgrade to Buy from Neutral at Bank of Bank of America.

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines ...

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...